Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

8.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.7K
Coagulation01:06

Coagulation

612
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
612
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.6K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

12.5K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Complications of Pulmonary Embolism: Which Is the Optimal Follow-Up?

Heart failure clinics·2026
Same author

Long-Term Outcomes After Catheter-Directed Thrombolysis or Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism: A Propensity-Matched Analysis From a TriNetX Database.

Pulmonary circulation·2026
Same author

Impact of concomitant deep vein thrombosis on outcomes of acute pulmonary embolism: Insights from the PERT consortium registry.

Journal of vascular surgery. Venous and lymphatic disorders·2026
Same author

Major Bleeding Rates Associated With Catheter-Directed Therapies in Patients With Intermediate-Risk Pulmonary Embolism.

JACC. Advances·2026
Same author

Sotatercept in Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension: A Case Series and Systematic Review.

Pulmonary circulation·2026
Same author

Post-Pulmonary Embolism Syndrome: New Phenotypes Come into Focus.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Nov 14, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

993

Coagulopathy in COVID-19.

Ka U Lio1, Parth Rali2

  • 1Medical student, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Lung India : Official Organ of Indian Chest Society
|March 9, 2021
PubMed
Summary
This summary is machine-generated.

Severe COVID-19 is linked to hemostatic derangement, with elevated D-dimer and fibrinogen degradation products. Many nonsurvivors met criteria for disseminated intravascular coagulation (DIC), highlighting coagulation

Keywords:
Acute respiratory distress syndromeCOVID-19D-dimeranticoagulantcoagulopathydisseminated intravascular coagulopathyheparin

More Related Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.1K

Related Experiment Videos

Last Updated: Nov 14, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

993
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.1K

Area of Science:

  • Coagulation and Thrombosis
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Severe COVID-19 presents with significant hemostatic abnormalities.
  • Elevated D-dimer and fibrinogen degradation products are common in severe cases.
  • Disseminated intravascular coagulation (DIC) affects a high percentage of non-survivors.

Purpose of the Study:

  • To review the role of hemostasis in COVID-19 pathogenesis.
  • To evaluate the impact of hemostatic derangements on disease severity.
  • To discuss hemostasis in the management of COVID-19.

Main Methods:

  • Literature review of studies on COVID-19 and hemostasis.
  • Analysis of clinical data regarding coagulation markers.
  • Evaluation of diagnostic criteria for DIC in COVID-19 patients.

Main Results:

  • Hemostatic derangement is a key feature of severe COVID-19.
  • High prevalence of elevated coagulation markers and DIC in non-survivors.
  • Coagulation abnormalities contribute to COVID-19 severity.

Conclusions:

  • Understanding hemostasis is crucial for managing severe COVID-19.
  • Targeting coagulation pathways may be essential for improving patient outcomes.
  • Further research into COVID-19-associated coagulopathy is warranted.